HeyJaredLancet Rheumatol
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 28, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 27, 2026
Latest articles
Is Rozanolixizumab Effective in Severe Fibromyalgia? (opens the original)
Read excerpt
Rozanolixizumab, an antibody targeting the neonatal Fc receptor for immunoglobulin G (IgG), showed modest improvement in pain interference and fibromyalgia impact among patients with severe fibromyalgia but did not significantly reduce pain intensity or fatigue. The primary endpoint met the prespecified one-sided statistical threshold but not the standard two-sided significance level. "The small sample size and marked heterogeneity in patient responses limit interpretability of findings. Further
B-Cell Depletion Tied to Rituximab Response in Myopathies (opens the original)
Read excerpt
Complete depletion of memory B cells and plasmablasts within 2 weeks of rituximab infusion was associated with clinical response in patients with idiopathic inflammatory myopathies (IIM), and highly sensitive flow cytometry (HSFC) detected these differences, while conventional flow cytometry did not. "Although these findings require prospective validation, combining HSFC-defined minimal residual disease assessment with autoantibody profiling could help to uncover the pathogenic B-lineage program
Does Tapering TNF Inhibitors Maintain Low Disease Activity? (opens the original)
Read excerpt
A treat-to-target tapering strategy for TNF inhibitors appeared to maintain low disease activity for up to 2 years in patients with psoriatic arthritis and axial spondyloarthritis. "[T]hese data indicate that a taper-to-target strategy is effective and leads to substantial TNF inhibitor dose reduction, but optimal execution of such a strategy in routine care is more challenging than in the context of a clinical trial," the authors of the study wrote. The study was led by Amy C.D. Peeters, MD, Si
Early Screening Linked to Better Outcomes in RA (opens the original)
Read excerpt
Patients with rheumatoid arthritis (RA) referred through an early arthritis recognition clinic experienced significantly less functional disability and had more than twice the likelihood of sustained disease-modifying antirheumatic drug (DMARD)-free remission over 5 years compared with those referred through regular pathways. "The [study] results, therefore, have great added value because they indicate that an active intervention leading to an earlier diagnosis of rheumatoid arthritis, in combin
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.